Evidence map›Paper›PMID 41786885›Full record

ArticleNPJ precision oncology2026

GLUD1 supports ovarian cancer progression by counteracting anoikis via ARAF/MEK/ERK signaling.

Huolun Feng, Yanzhen Chen, Geyan Wu, Zhentao Zhang, Hongkun Lai, Changnian Yang, Shaofen Zhang, Yongqing Lin, Yingqi Liu, Haiyan Ye and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Huolun Feng *Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangzhou, Guangdong, China.
Yanzhen Chen *Department of Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Geyan Wu *Biomedicine Research Centre, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Zhentao ZhangThe First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, Guangdong, China.
Hongkun LaiDepartment of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Changnian YangThe First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, Guangdong, China.
Shaofen ZhangDepartment of Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Yongqing LinDepartment of Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Yingqi LiuThe First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, Guangdong, China.
Haiyan YeDepartment of Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China. yehaiyan@gdph.org.cn.
Shanshan WuDepartment of Biology, School of Basic Medical Sciences, Guangdong Medical University, Zhanjiang, Guangdong, China. wushsh@gdmu.edu.cn.
Lixue CaoMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China. caolixue@gdph.org.cn.

Funding

College Students' Innovative Entrepreneurial Training Plan Program S202510571044Guangdong Basic and Applied Basic Research Foundation 2022A1515010243Guangdong Basic and Applied Basic Research Foundation 2025A1515012496Guangzhou Municipal Science and Technology Project 2024A04J3475Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation No.pdjh2025bk102
6 · The paper itself

Abstract

Peritoneal dissemination is the major cause of mortality in epithelial ovarian cancer (EOC) and requires tumor cells to survive in a detached state by evading anoikis. However, the molecular mechanisms supporting anchorage-independent survival remain poorly defined. Here, we identify glutamate dehydrogenase 1 (GLUD1) as a key regulator of anoikis resistance and metastatic progression in EOC. GLUD1 expression was elevated in metastatic EOC tissues and associated with unfavorable clinical outcomes. Loss of GLUD1 impaired anoikis resistance and reduced metastatic capacity of ovarian cancer cells in vitro, while markedly suppressing peritoneal dissemination and prolonging survival in vivo. Mechanistically, GLUD1 was found to interact with a key protein ARAF, the A-Raf proto-oncogene. By limiting ubiquitin-proteasome-mediated degradation of ARAF, GLUD1 exerted a non-enzymatic function that stabilized ARAF protein levels and sustained MEK/ERK signaling.Together, these findings reveal a non-canonical role of GLUD1 in regulating protein stability and identify the GLUD1-ARAF axis as a critical mechanism supporting anchorage-independent survival during peritoneal dissemination of EOC.

Identifiers

PMID41786885
PMCPMC13079734

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.